Visiox Pharmaceuticals has announced that it has entered into a merger agreement with Ocuvex Therapeutics, a privately held pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders.

The merger is expected to increase Ocuvex’s market presence and accelerate the commercialization of Visiox’s products, including Omlonti (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine) 0.35%, and SDN-037 (difluprednate) 0.04%. Going forward, the company will operate under the Ocuvex name.

“The combination of Visiox and Ocuvex makes for a perfect match,” said Ryan S. Bleeks, chief executive officer of Visiox, in a press release. “We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care.”